FDA's Overreach on Compounded Peptides FDA Peptide Reclassification 2026: What Researchers Want BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health